



(51) International Patent Classification:

A61P 13/12 (2006.01) *A61K 39/00* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2021/051753

(22) International Filing Date:

26 January 2021 (26.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


62/966,258 27 January 2020 (27.01.2020) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **BAKER, David, James**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **HEASMAN, Stephanie, Claire**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **HERRERA, Maria, Marcela**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **LIARTE MARIN, Elena**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **MORENO-QUINN, Carol, Patricia**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **MURRAY, Lynne, Anne**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **TSUI, Ping**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **WU, Yanli**;

(54) Title: ANTI- α V β 8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE

FIG. 1A



(57) Abstract: Provided are methods and compositions for treating kidney disease, such as chronic kidney disease (CKD), in which the methods and compositions comprise antibodies or an antigen binding fragment thereof that specifically and selectively bind to human α V β 8 integrin, which was discovered, as described, to be highly expressed on kidney cells and tissue, and, in particular, diseased or fibrotic kidney tissue. The disclosed anti- α V β 8 integrin antibodies bind to human α V β 8 integrin in the kidney and block the activation of TGF- β from its latent form in kidney tissue. The anti- α V β 8 antibodies in the disclosed methods reduce, attenuate, or abrogate kidney fibrosis, which is associated with the activities of α V β 8 integrin and TGF- β in kidney tissue. The disclosed antibodies and methods effectively treat kidney disease, in particular, fibrosis associated with kidney disease, such as CKD, in individuals in need thereof.

[Continued on next page]

MedImmune, LLC, One MedImmune Way, Gaithersburg,
Maryland 20878 (US).

(74) **Agent: TTOFI, Evangelia et al.;** AstraZeneca Intellectual
Property Milstein Building, Granta Park, Cambridge Cam-
bridge CB21 6GH (GB).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*